Debiopharm, announced having reached an agreement with Meridian Bioscience. for Meridian to acquire GenePOC’s (Canadian affiliate of Debiopharm) molecular diagnostics business portfolio. This decision was made in response to the need to identify a partner with a solid commercialization capacity, in order to quickly offer the benefit of GenePOC’s rapid, high-quality diagnostics testing to patients, supporting diagnosis and guidance towards targeted therapeutic decisions for infectious diseases.
Debiopharm became the major shareholder of GenePOC in July 2016. Over years of collaboration, ongoing clinical development led to a number of achievements including FDA approval and European CE marking of the revogene® device and 3 rapid molecular assays for Group A and B Streptococcus along with the Clostridium difficile test. Recently, the Carba assay also received CE marking certification. With these approved assays and a robust pipeline GenePOC has become a key player in the development of rapid diagnostic tools.
Meridian Bioscience has a long, proven history in both the laboratory diagnostics and life sciences markets. Meridian develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies. With an extensive commercial infrastructure and experienced sales force in the U.S., Europe and other major markets, the company targets hospitals, specialized laboratories, research centers, diagnostic manufacturers and companies with its broad offering.
“When we integrated GenePOC into Debiopharm, the main objective was to quickly bring their instrument and diagnostic tests to market approval. As antibiotic resistance is a major public health issue, it has become urgent to offer patients rapid diagnostic tools to guide therapies targeting the precise pathogen. Meridian’s extensive commercial infrastructure and their undisputed experience make it an ideal partner for GenePOC. After nearly 4 years of collaboration, it is difficult to part ways, but we are happy to have successfully achieved our objectives together. I am deeply grateful to the entire team for their ongoing commitment.”
– Thierry Mauvernay, President of Debiopharm
“We are very excited to be adding the GenePOC technology and team to Meridian. GenePOC provides an exciting, new state-of-the-art molecular diagnostics platform to our Diagnostics portfolio. This is a critical element of our strategy to re-position our Diagnostics business for sustainable long-term growth. GenePOC’s revogeneTM platform is an excellent fit for our customers and strategy to offer gastrointestinal-focused and other targeted diagnostic solutions to meet the diverse needs of more complex health care system. We welcome the GenePOC team to the Meridian family and look forward to continuing our very good relationship with Debiopharm into future.”
– Jack Kenny, Chief Executive Officer, Meridian Bioscience
Related Reports and Monitors
Medical Wearables: Market and Technology Trends 2019
Market & Technology
CRISPR Technology & Market Overview: from Lab to Industry 2018
Market & Technology